This follows up on an old thread from the NSTK board that spilled over to iHub. By defining FSD broadly to include HSDD, PTN is only hurting itself, IMHO. True, the broad definition will facilitate patient enrollment. But it will also make the enrolled population more heterogeneous and this may make it harder for the trial to meet its efficacy endpoints.
FSD and female HSDD are two distinct medical conditions. Trying to treat them as one could backfire.
Market Data 
Markets 
AI
